Moberg Pharma (Sweden)
company in Bromma, Sweden
MOB Nasdaq Stockholm
ISIN SE0020353928 LEI 549300XFXK7DVGDRP410
Follow Moberg Pharma (Sweden)
Weekly email: filings, results
Revenue, last year
SEK 13.5M
+38% vs prior year
Net income
−SEK 27.2M
+89.3% vs prior year
EPS, diluted
−SEK 0.58
+91.4% vs prior year
Operating cash flow
−SEK 17.5M
−6.2% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | SEK 13.5M | −SEK 27.2M |
| FY24 | SEK 9.8M | −SEK 255.1M |
| FY23 | SEK 0 | −SEK 21.1M |
| FY22 | SEK 207K | −SEK 15.7M |
| FY21 | SEK 0 | SEK 7.5M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 56.7% | −201.8% | −201.2% |
| FY24 | 64.4% | −3310.9% | −2600.3% |
| FY23 | - | - | - |
| FY22 | 100% | −9771% | −7589.4% |
| FY21 | - | - | - |